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ABSTRACT: D-Pen2,D-Pen5 enkephalin (DPDPE) is one of the most selective synthetic peptide agonist targeting the δ-opioid re-
ceptor. Three cyclic analogues of DPDPE containing a xylene bridge in place of disulphide bond have been synthesized and fully 
characterized as opioid receptors agonists. The in vitro activity was investigated showing a good affinity of 7a-c for µ and δ-
receptors. In vivo biological assays revealed that 7b is the most potent analogue with the ability to maintain high level of analgesia 
from 15 to 60 minutes following intracerebroventricular (i.c.v.) administration, whereas DPDPE was slightly active until 45 min. 
7b induced long lasting analgesia also after subcutaneous administration, whereas DPDPE was inactive. 
The cloning of  opioid receptors has provided direct struc-
tural evidence of the “multiple opioid receptors” concept as 
powerful tools for physiological and pharmacological evalua-
tion of their roles in both normal and acute pain states.1-2  
Delta-opioid receptors (DOP) are appealing drug targets for 
pain relief, due to the lack of unwanted side effects and the 
strong antinociceptive activity showed by their selective ago-
nists. Ligands possessing dual agonist activities at the δ- and 
µ-receptors may allow for the effective treatment of pain with 
lessened µ-receptor-mediated side effects.3 Thus, it is highly 
desirable the design of “unbalanced” dual-acting opioid drugs 
as full δ-opioid receptor agonist and only as partial agonist of 
the µ-opioid receptor, which is strongly related to the devel-
opment of tolerance and physical dependence.4 Met-
Enkephalin and Leu-Enkephalin are linear endogenous penta-
peptides with high affinity for DOP regulating human nocicep-
tion; numerous structural modifications have been explored 
during the last years to investigate the structure activity rela-
tionships (SAR) and to improve their selectivity;5,6 H-Tyr-c[D-
Pen-Gly-Phe-D-Pen]-OH (DPDPE) is the first synthetic proto-
type of highly selective constrained cyclic peptide for this re-
ceptor (Figure 1).7 
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Figure 1. DPDPE cyclization strategy from Leu/Met-
Enkephalins. 
 
DPDPE is employed as radio-labeled δ receptor full agonist 
in the opioid binding assays due to its resistance to proteolytic 
degradation and permeability to the blood-brain barrier 
(BBB).8 
The X-ray crystal structure of DPDPE published in 1994,9 
has been assumed as starting point in a recent computational 
study based on MD simulations,10 from which a series of puta-
tive bioactive conformations has been provided: Gem-
dimethyl groups of the D-Penicillamine residues are responsi-
ble for the rigidified structure and their adverse steric interac-
tions for the low µ-opioid (MOP) receptor affinity. Disulphide 
bond is prone to reduction following ring opening, so incorpo-
ration of different types of linkers could provide conforma-
tional diversity involving different cyclization strategies, glob-
al and local constrictions;7 the replacement of disulphide bond 
with more stable bridges can increase metabolic stability and 
change the overall conformation, in order to improve the re-
ceptor binding affinity of the novel compounds.11,12 A system-
atic and synergistic multi-disciplinary approach has been used, 
over the last decades, for the design of novel peptide ligands 
with unique biological activity profiles.13 In this paper we pro-
pose the design, synthesis and biological evaluation of new 
cyclic DPDPE analogues 7a-c containing o-, m-, p-xylene re-
gioisomers respectively as µ/δ mixed opioid receptor agonists, 
using in vitro and in vivo models to examine the antinocicep-
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 tion activity of the new entities. The C-terminal free carboxyl 
group in DPDPE improves the δ/µ selectivity,14 then it has 
been maintained in our cyclic peptides. We envisaged that the 
introduction of different disulphide bridge in DPDPE would 
lead to different µ/δ affinity, increased stability and activity of 
the newly designed peptides; according to this working hy-
pothesis, a side-chain-to-side-chain cyclization involving the 
two thiols groups and three dibromo-xylene regioisomers has 
been performed. The xylene-type bridging reaction utilizes the 
exquisite reactivity of dibromo-xylene scaffolds toward free 
thiols groups of penicillamine residues of compound 4,15 
providing cyclic peptides containing two robust thioether 
bonds (5a-c). The novel cyclic peptides 7a-c have been also 
investigated by molecular docking study, to discern the struc-
tural influences of different xylene regioisomers on the molec-
ular interactions of the cyclic peptides at the δ-opioid recep-
tors. Other similar organic scaffolds may offer new insights 
for the preparation of further constrained DPDPE analogues 
(e.g. N-substituted bromomaleimide motif),16 and could be se-
lected for future development. 
  
 
Scheme 1. Synthesis of final compounds 7a-c. Reagents and 
Conditions. (a) 1.1 equiv BocPhe-OH, 1.1 equiv EDC.HCl, 1.1 
equiv HOBt anhydrous, 3.3 equiv DIPEA, DMF under N2 at-
mosphere, r.t., overnight; (b) TFA/DCM = 1:1 under N2 at-
mosphere, r.t., 1h; (c) 1.1 equiv BocGly-OH, 1.1 equiv 
EDC.HCl, 1.1 equiv HOBt anhydrous, 3.3 equiv DIPEA, DMF 
under N2 atmosphere, r.t., overnight; (d) 1.1 equiv Boc(D)Pen-
OH, 1.1 equiv EDC.HCl, 1.1 equiv HOBt anhydrous, 3.3 
equiv DIPEA, DMF under N2 atmosphere, r.t., overnight; (e) 
2.1 equiv of o-dibromo-xylene, 6 days for 5a, 1.3 equiv of m-
dibromo-xylene, 4 days for 5b, 2.1 equiv of p-dibromo-xylene, 
6 days for 5c, 2.6 equiv DIPEA in DMF under N2 atmosphere, 
r.t.; (f) 1.1 equiv BocTyr-OH, 1.1 equiv EDC.HCl, 1.1 equiv 
HOBt anhydrous, 3.3 equiv DIPEA, DMF under N2 atmos-
phere, r.t., overnight; (g) 4 equiv NaOH 1M in THF, 5h for 7a, 
2 equiv NaOH 1M in THF, 2h for 7b, 3.5 equiv NaOH 1M in 
THF, 3h for 7c, r.t.      
Solution phase peptide synthesis has been performed fol-
lowing the standard method of EDC.HCl/HOBt anhy-
drous/DIPEA in DMF,17 in accordance with Boc protection 
strategy to afford the three cyclic peptides 7a-c as TFA salts 
(for the general procedures see SI). The commercially availa-
ble D-Penicillamine has been converted in its methyl ester de-
rivative 1 following the well-established literature procedure,18 
and then it was submitted to coupling reaction with BocPhe-
OH. Coupling reactions have been repeated together with Boc-
deprotection cocktail treatment, until to reach the key interme-
diate compound Boc-(D)Pen-Gly-Phe-(D)Pen-OMe (4), which 
was used for the subsequent cyclization reaction (Scheme 1).  
Based on the work of Benito and Meldal on bicyclic organo-
peptides19 we applied the same chemoselective cyclization re-
action relying on the chemical linkage of peptides onto scaf-
folds (CLIPS) technology,20 to afford our desired cyclic inter-
mediates 5a-c in 51%, 63% and 39% yields respectively, after 
silica gel chromatography. The reaction between linear inter-
mediate 4 and 1.3 equiv. of m-dibromo-xylene is completed 
after 4 days, while the cyclization reaction to form 5a,c re-
quires 1 week to reach the completeness with 2.1 equiv. of al-
kylation reagent; this is possibly due to the steric hindrance of 
halogen atoms in o-dibromo-xylene, which makes difficult the 
attack of the two thiols groups; in the opposite case, the dis-
tance between the two bromine atoms in the p-substituted re-
gioisomer, hampers the ring closure, thus prolonging further 
the reaction time and requiring more equivalents of reagent. 
Then the Boc protecting group has been removed from 5a-c 
and Boc-Tyr-OH has been attached to obtain the full cyclic 
sequences 6a-c. Finally, saponification under basic condition 
occurred following the same behavior of the side chain-to-side 
chain cyclization in terms of time and reagents converting the 
free acids compounds into the corresponding TFA salts. The 
purification by RP-HPLC chromatography allowed to obtain 
the desired cyclic peptides 7a-c with a grade of purity ≥ 95% 
in 41%, 55% and 40% overall yields respectively. Analysis of 
cyclic penta peptides incorporating thioether bridge is tricky 
and complex in order to achieve a rigorous proof of structure; 
according to a recent paper by Johnson et al.,21 full characteri-
zation of the final products 7a-c has been performed through 
MS-UPLC (Figures S1-S3), analytical RP-HPLC and 1H-
NMR.  
 
 
 
 
 (Ki) Ratio 
Cpds. [3H]IleDelt II (δ) [3H]DAMGO (µ) µ/δ 
DPDPE  (4.5 nM)  (438.1 nM) 97.3 
7a  (16.9 nM)  (115 nM) 6.7 
7b (34.9 nM) (292.2 nM) 8.3 
7c  (546 nM)  (249 nM) 0.5 
 
Table 1. The affinity values (logIC50 ± S.E.M. and Ki) and 
µ/δ selectivity ratios of 7a-c compounds and DPDPE in 
[3H]IleDelt II and [3H]DAMGO competition binding assays in 
rat brain membrane homogenates. The logIC50 and Ki values 
were calculated based on the competition binding curves seen 
in Figure S4. 
 
The method applied resulted to be efficient and straightfor-
ward to furnish exhaustive qualitative and structural infor-
mation on our novel molecular entities, which were used for 
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 the competition binding assays versus µ and δ-opioid recep-
tors;22,23 all the cyclic compounds 7a-c showed good binding 
profile for δ-opioid receptor, although they displayed a lower 
affinity than DPDPE (Figure S4, Table 1). However, they 
showed a considerable higher affinity for µ-opioid receptor 
compared to DPDPE, indicating that the structural modifica-
tions on the parent compound significantly reduced its δ-
opioid receptor selectivity (Table 1). This behavior closely re-
sembles that of small cycle enkephalin analogues containing a 
thiourea bridge.6 In particular, cyclic peptide 7a had the best Ki 
value for DOR and MOR (Table 1).  
 
Antinociception assays have been also carried out to inves-
tigate the in vivo potential activity of the newly designed com-
pounds.24,25 From the tail flick (TF) and hot plate (HP) tests we 
observed that compound 7b exerted a potent analgesic effect 
over 60% MPE, ranging from 15 to 60 minutes, after i.c.v. 
administration; this result has been also confirmed by formalin 
test (Figure 2). The compounds 7a-c and DPDPE were docked 
to the δ-opioid receptor (PDB:4RWD) to explore the impact of 
xylene bridge incorporation on the biological activity profile. 
This has been carried out by using Glide tool embedded in 
maestro 9.2 and employing the generated grid around 10Å 
from the crystallographic ligand H-Dmt-Tic-Phe-Phe-NH2 
(DIPP-NH2).
26 
The best docking pose for each ligand was selected basing 
on XP scoring function. The interaction between residue 
Asp128 and the amino terminus of each ligand is the most im-
portant and was preserved in all 5 models; the orientation of 
Tyr amino acid is overall very similar (Figure 3). 
 
 
 
 
Figure 2. Tail Flick, Hot plate and Formalin Test assays on 
cyclic peptides 7a-c. V is for vehicle, D is for DPDPE. In the 
HP and TF test, drugs were injected i.c.v. at the dose of 23 
nmol/mouse. In the formalin test, drugs were administered s.c. 
at the dose of 150 nmol/mouse, 15 minutes before formalin. 
**** is for P<0.0001, *** is for p<0.001, ** is for p<0.01, * is 
for p<0.05 vs D. N=8-10. 
 
The interaction with residue Arg192 has been also main-
tained in 7a and 7c, but 7b gained the best docking score; its 
docking pose is stabilized by hydrogen bonds with residues 
Asp128, Lys214 and a saline bridge with Lys108 (Figure S5). 
It is worth noting that the xylene bridge enclosed in 7a-c is 
topically very similar to the Tic moiety present in DIPP-NH2.
26 
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Figure 3. Best docking poses of DPDPE (A), compound 7a 
(B), compound 7b (C) and compound 7c (D) at the DOR (only 
the involved residues are depicted). 
 
However, an important difference is the orientation of the 
fourth aromatic ring, which may discriminate the agonist vs 
antagonist activity of the DPDPE cyclic analogues vs the crys-
tallographic ligand DIPP-NH2 (Figure S6).
26,27 
Simple variation of xylene bridge regioisomer in a small cy-
cle greatly impacts the biological activity, while maintaining 
the same peptide sequence. Considering that xylene substitu-
tion could influence the bridge orientation rendering the cycle 
less flexible and leading to a less favorable conformation, 
compound 7b incorporating m-xylene bridge represent an ex-
quisite example of well-balanced equilibrium between δ-
opioid receptor affinity and analgesic potency. Compound 7b 
was tested in vivo displaying antinociceptive activity in TF, 
HP and Formalin test, after i.c.v. and subcutaneous injections. 
Our data validate the hypothesis that the design of novel 
chemical entities specifically targeted at known receptors will 
provide vantages for pain-relief in many pathological situa-
tions. Local peripheral administration of opioid endeavored 
antinociceptive effects in chronic inflammatory conditions,28,29 
although this effect was reached at relatively high doses. Pre-
vious report showed that DPDPE induced antinociceptive ef-
fects after subcutaneous administration in the formalin test, 
but in the second phase only.30  
Our data demonstrate that the novel compounds induced ro-
bust and long-lasting antinociceptive effects both after central 
and local peripheral administration. 
 
EXPERIMENTAL SECTION 
Methods and Materials. Boc-protected amino acids, 
EDC.HCl, HOBt anhydrous, DIPEA, solvents and other rea-
gents were purchased from Sigma-Aldrich (Milano) and Iris-
Biotech (Germany) and were used without further purification. 
Solvents for RP-HPLC and ESI-MS were of HPLC grade. All 
the reactions were conducted under nitrogen atmosphere. Final 
products 7a-c were purified by RP-HPLC using a Waters 
XBridge Prep BEH130 C18, 5.0 µm, 250 mm × 10 mm col-
umn at a flow rate of 4 mL/min on a Waters Binary pump 
1525, using as eluent a linear gradient of H2O/acetonitrile 
0.1% TFA ranging from 5% acetonitrile to 90% acetonitrile in 
45 min. The purity of the Nα-Boc-protected products was con-
firmed by NMR analysis on a Varian Inova 300 MHz and 
mass spectrometry ESI-LRMS. The purity of all final TFA 
salts was confirmed by NMR analysis, ESI-LRMS, and analyt-
ical RP-HPLC (C18-bonded 4.6 mm × 150 mm) at a flow rate 
of 1 mL/min, using as eluent a gradient of H2O/acetonitrile 
0.1% TFA ranging from 5% acetonitrile to 95% acetonitrile in 
50 min and was found to be ≥95%. 1H NMR spectra were per-
formed in DMSO-d6 solution on a Varian Inova operating at 
the 1H frequency of 300 MHz. Chemical shifts were referred 
to the residual proton signal of DMSO at 2.5 ppm. Peptide 
structures were also confirmed by UPLC-MS (see SI).  
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N,N-dimethylformamide; DMSO, dimethyl sulfoxide; DOR, δ 
opioid receptor; EDC, 1-ethyl-(3-
dimethylaminopropyl)carbodiimide; HOBt, 1-
hydroxybenzotriazole; MOR, µ opioid receptor; MVD, mouse vas 
deferens; DIPEA, N,N-diisopropylethylamine; RP-HPLC, re-
versed phase high performance liquid chromatography; TFA, tri-
fluoroacetic acid; THF, tetrahydrofuran; TMS, tetramethylsilane; 
MS-UPLC, ultra-performance liquid-chromatography tandem 
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